×
Biofrontera Total Liabilities 2021-2025 | BFRI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biofrontera total liabilities from 2021 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Biofrontera Total Liabilities 2021-2025 | BFRI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biofrontera total liabilities from 2021 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$228.5B
Amgen (AMGN)
$165.9B
Gilead Sciences (GILD)
$140.8B
Vertex Pharmaceuticals (VRTX)
$121.3B
Bristol Myers Squibb (BMY)
$99.6B
CSL (CSLLY)
$86.2B
GSK (GSK)
$78.3B
Regeneron Pharmaceuticals (REGN)
$61B
Alnylam Pharmaceuticals (ALNY)
$42.8B
Argenex SE (ARGX)
$36.2B
BioNTech SE (BNTX)
$27.5B
Royalty Pharma (RPRX)
$20.6B
Insmed (INSM)
$19.6B
Biogen (BIIB)
$19.4B
Illumina (ILMN)
$17B
Genmab (GMAB)
$15.2B
Genmab (GNMSF)
$14.9B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.2B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.5B
QIAGEN (QGEN)
$11.4B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.3B
Exact Sciences (EXAS)
$9.2B
Bio-Techne Corp (TECH)
$9.2B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.3B
Legend Biotech (LEGN)
$8.1B
Roivant Sciences (ROIV)
$7.7B